Bulantı ve Kusma
Özet
Kemoterapi, hedefe yönelik tedaviler ve immünoterapi gibi antikanser tedavilerin neden olduğu bulantı ve kusma, hastanın yaşam kalitesini önemli ölçüde etkileyerek tedavide uyumsuzluğa yol açabilir. Bulantı ve/veya kusma, hastalarda sıvı kaybına, metabolik bozukluklara, gıda alımında azalmaya, hastanın fiziksel ve zihinsel performansında düşmeye neden olabilir. Bulantı ve/veya kusmanın sıklığı ve şiddeti kullanılan terapotik ajanın çeşidi, dozu, uygulama yolu, radyoterapi uygulanıyor ise hedef anatomik bölge gibi çok sayıda faktörden etkilenir. Kusmanın patofizyolojisi göz önüne alındığında kusmaya neden olan faktörlerin erken tespiti, profilaktik antiemetik rejimler ile kusmanın önlenmesi veya azaltılması hasta ve tedavi sürekliliği açısından önemlidir.
Nausea and vomiting caused by anticancer treatments such as chemotherapy, targeted therapies, and immunotherapy can significantly affect the patient's quality of life and lead to noncompliance with treatment. Nausea and/or vomiting can cause dehydration, metabolic disorders, decreased food intake, and decreased physical and mental performance in patients. The frequency and severity of nausea and/or vomiting are affected by many factors such as the type of therapeutic agent used, dose, route of administration, and target anatomical region if radiotherapy is applied. Considering the pathophysiology of vomiting, early detection of the factors that cause vomiting and prevention or reduction of vomiting with prophylactic antiemetic regimens are important for the patient and treatment continuity.
Referanslar
Navari RM, Aapro M. Antiemetic prophylaxis for chemotherapy- induced nausea and vomiting. N Engl J Med 2016;374:1356-1367.
Herrstedt J. Antiemetics: an update and the MASCC guidelines applied in clinical practice. Nat Clin Pract Oncol 2008;5:32-43.
American Gastroenterological A. American Gastroenterological Association medical position statement: nausea and vomiting. Gastroenterology 2001;120:261-263.
Craig JB, Powell BL. The management of nausea and vomiting in clinical oncology. Am J Med Sci 1987;293:34-44.
Borison HL, Wang SC. Physiology and pharmacology of vomiting. Pharmacol Rev 1953;5:193-230.
Seigel LJ, Longo DL. The control of chemotherapy-induced emesis. Ann Intern Med 1981;95:352-359.
Dodds LJ. The control of cancer chemotherapy-induced nausea and vomiting. J Clin Hosp Pharm 1985;10:143-166.
Chow R, Chiu L, Navari R, et al. Efficacy and safety of olanzapine for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV) as reported in phase I and II studies: a systematic review. Support Care Cancer 2016;24:1001-1008.
Warr DG, Street JC, Carides AD. Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of phase 3 trial of aprepitant in patients receiving adriamycin-cyclophosphamide-based chemotherapy. Support Care Cancer 2011;19:807-813.
Kris MG, Gralla RJ, Clark RA, et al. Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin. J Clin Oncol 1985;3:1379-1384.
Roila F, Boschetti E, Tonato M, et al. Predictive factors of delayed emesis in cisplatin-treated patients and antiemetic activity and tolerability of metoclopramide or dexamethasone. A randomized single-blind study. Am J Clin Oncol 1991;14:238-242.
Moher D, Arthur AZ, Pater JL. Anticipatory nausea and/or vomiting. Cancer Treat Rev 1984;11:257-264.
Jacobsen PB, Redd WH. The development and management of chemotherapy-related anticipatory nausea and vomiting. Cancer Invest 1988;6:329-336.
Morrow GR. Clinical characteristics associated with the development of anticipatory nausea and vomiting in cancer patients undergoing chemotherapy treatment. J Clin Oncol 1984;2:1170-1176.
Roila F, Hesketh PJ, Herrstedt J, Antiemetic Subcommitte of the Multinational Association of Supportive Care in C. Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference. Ann Oncol 2006;17:20-28.
Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: American society of clinical oncology clinical practice guideline update. J Clin Oncol 2017;35:3240-3261.
Feyer PC, Maranzano E, Molassiotis A, et al. Radiotherapy-induced nausea and vomiting (RINV): MASCC/ESMO guideline for antiemetics in radiotherapy: update 2009. Support Care Cancer 2011;19 Suppl 1:S5- 14.
Harding R, Young R, Anno G. Radiotherapy-induced emesis. In: Andrews P, Sanger G, eds. Emesis in Anti-Cancer Therapy. London: Chapman & Hall Medical; 1993:163-178.
Urba S. Radiation-induced nausea and vomiting. J Natl Compr Canc Netw 2007;5:60-65.
Maranzano E, Feyer P, Molassiotis A, et al. Evidence-based recommendations for the use of antiemetics in radiotherapy. Radiother Oncol 2005;76:227-233.
McKenzie E, Zaki P, Raman S, et al. Radiation-induced nausea and vomiting: a comparison between MASCC/ESMO, ASCO, and NCCN antiemetic guidelines. Support Care Cancer 2019;27:783-791.
Salvo N, Doble B, Khan L, et al. Prophylaxis of radiation-induced nausea and vomiting using 5-hydroxytryptamine-3 serotonin receptor antagonists: a systematic review of randomized trials. Int J Radiat Oncol Biol Phys 2012;82:408-417.
Roila F, Herrstedt J, Aapro M, et al. Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol 2010;21 Suppl 5:v232-243.
Galli JA, Sawaya RA, Friedenberg FK. Cannabinoid hyperemesis syndrome. Curr Drug Abuse Rev 2011;4:241-249.
Sakamoto A, Takayama H, Mamiya K, Koizumi T. Opioid withdrawal presenting only nausea during tapering of oxycodone after celiac plexus block: a case report. Ann Palliat Med 2016;5:67-70.
Hesketh PJ, Kris MG, Grunberg SM, et al. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 1997;15:103- 109.
Grunberg SM, Warr D, Gralla RJ, et al. Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity--state of the art. Support Care Cancer 2011;19 Suppl 1:S43-47.
Herrstedt J, Dombernowsky P. Anti-emetic therapy in cancer chemotherapy: current status. Basic Clin Pharmacol Toxicol 2007;101:143-150.
Hesketh PJ, Gandara DR. Serotonin antagonists: a new class of antiemetic agents. J Natl Cancer Inst 1991;83:613-620.
Riviere A. Dose finding study of granisetron in patients receiving high-dose cisplatin chemotherapy. The Granisetron Study Group. Br J Cancer 1994;69:967-971.
Jordan K, Hinke A, Grothey A, et al. A meta-analysis comparing the efficacy of four 5-HT3-receptor antagonists for acute chemotherapy- induced emesis. Support Care Cancer 2007;15:1023-1033.
Billio A, Morello E, Clarke MJ. Serotonin receptor antagonists for highly emetogenic chemotherapy in adults. Cochrane Database Syst Rev 2010:CD006272.
Botrel TE, Clark OA, Clark L, et al. Efficacy of palonosetron (PAL) compared to other serotonin inhibitors (5-HT3R) in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately or highly emetogenic (MoHE) treatment: systematic review and meta-analysis. Support Care Cancer 2011;19:823-832.
Boccia RV, Gordan LN, Clark G, et al. Efficacy and tolerability of transdermal granisetron for the control of chemotherapy-induced nausea and vomiting associated with moderately and highly emetogenic multi- day chemotherapy: a randomized, double-blind, phase III study. Support Care Cancer 2011;19:1609-1617.
Howell J, Smeets J, Drenth HJ, Gill D. Pharmacokinetics of a granisetron transdermal system for the treatment of chemotherapy- induced nausea and vomiting. J Oncol Pharm Pract 2009;15:223-231.
Seol YM, Kim HJ, Choi YJ, et al. Transdermal granisetron versus palonosetron for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: a multicenter, randomized, open-label, cross-over, active-controlled, and phase IV study. Support Care Cancer 2016;24:945-952.
Doggrell SA, Hancox JC. Cardiac safety concerns for ondansetron, an antiemetic commonly used for nausea linked to cancer treatment and following anaesthesia. Expert Opin Drug Saf 2013;12:421-431.
United States Food and Drug Administration. Anzemet (dolasetron mesylate): Drug safety communication - reports of abnormal heart rhythms. 2010.
Brygger L, Herrstedt J, Academy of Geriatric Cancer R. 5- Hydroxytryptamine3 receptor antagonists and cardiac side effects. Expert Opin Drug Saf 2014;13:1407-1422.
United States Food and Drug Administration. FDA drug safety communication: New information regarding qt prolongation with ondansetron (zofran). 2012.
Grunberg SM, Koeller JM. Palonosetron: a unique 5-HT3-receptor antagonist for the prevention of chemotherapy-induced emesis. Expert Opin Pharmacother 2003;4:2297-2303.
Aapro MS, Grunberg SM, Manikhas GM, et al. A phase III, double- blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol 2006;17:1441-1449.
Saito M, Aogi K, Sekine I, et al. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. Lancet Oncol 2009;10:115-124.
Gregory RE, Ettinger DS. 5-HT3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting. A comparison of their pharmacology and clinical efficacy. Drugs 1998;55:173-189.
Gralla RJ, de Wit R, Herrstedt J, et al. Antiemetic efficacy of the neurokinin-1 antagonist, aprepitant, plus a 5HT3 antagonist and a corticosteroid in patients receiving anthracyclines or cyclophosphamide in addition to high-dose cisplatin: analysis of combined data from two Phase III randomized clinical trials. Cancer 2005;104:864-868.
Hesketh PJ, Grunberg SM, Gralla RJ, et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Group. J Clin Oncol 2003;21:4112-4119.
Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, et al. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America.
Ottoboni T, Keller MR, Cravets M, et al. Bioequivalence of HTX-019 (aprepitant IV) and fosaprepitant in healthy subjects: a Phase I, open- label, randomized, two-way crossover evaluation. Drug Des Devel Ther 2018;12:429-435.
Grunberg S, Chua D, Maru A, et al. Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE. J Clin Oncol 2011;29:1495-1501.
Chau E, Lundberg J, Phillips G, et al. Updated report on incidence of infusion-site reactions associated with peripheral intravenous administration of fosaprepitant. J Oncol Pharm Pract 2019;25:1053- 1057.
Leal AD, Kadakia KC, Looker S, et al. Fosaprepitant-induced phlebitis: a focus on patients receiving doxorubicin/cyclophosphamide therapy. Support Care Cancer 2014;22:1313-1317.
Hesketh PJ, Rossi G, Rizzi G, et al. Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study. Ann Oncol 2014;25:1340-1346.
Hesketh PJ, Bohlke K, Lyman GH, et al. Antiemetics: American society of clinical oncology focused guideline update. J Clin Oncol 2016;34:381-386.
Aapro M, Rugo H, Rossi G, et al. A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy. Ann Oncol 2014;25:1328-1333.
Schwartzberg LS, Rugo HS, Aapro MS. New and emerging therapeutic options for the management of chemotherapy-induced nausea and vomiting. Clin Adv Hematol Oncol 2015;13:3-13, 11; quiz 12 p following 14.
Schwartzberg LS, Modiano MR, Rapoport BL, et al. Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide regimens in patients with cancer: a randomised, active-controlled, double-blind, phase 3 trial. Lancet Oncol 2015;16:1071-1078.
Rapoport BL, Chasen MR, Gridelli C, et al. Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients with cancer: two randomised, active-controlled, double-blind, phase 3 trials. Lancet Oncol 2015;16:1079-1089.
Clinical Trial J Clin Oncol 1998 Sep;16(9):2937-42. doi: 10.1200/JCO.1998.16.9.2937.Double-blind, dose-finding study of four intravenous doses of dexamethasone in the prevention of cisplatin-induced acute emesis. Italian Group for Antiemetic ResearchNo authors list PMID: 9738561 DOI: 10.1200/JCO.1998.16.9.2937
Clinical TrialJ Clin Onco 2004 Feb 15;22(4):725-9. doi: 10.1200/JCO.2004.09.040.Randomized, double-blind, dose-finding study of dexamethasone in preventing acute emesis induced by anthracyclines, carboplatin, or cyclophosphamide.
Yu H, Chen J, Zhou Y, et al. Impact of prophylactic dexamethasone on the efficacy of immune checkpoint inhibitors plus platinum-based chemotherapy in patients with advanced Non-Squamous Non-Small-Cell lung cancer. Int Immunopharmacol 2023;125:111138.
Muench J, Hamer AM. Adverse effects of antipsychotic medications. Am Fam Physician 2010;81:617-622.
Nakashima K, Murakami H, Yokoyama K, et al. A phase II study of palonosetron, aprepitant, dexamethasone and olanzapine for the prevention of cisplatin-based chemotherapy-induced nausea and vomiting in patients with thoracic malignancy. Jpn J Clin Oncol 2017;47:840-843.
Mukhopadhyay S, Dutta P, Banerjee S, et al. Low-dose olanzapine, sedation and chemotherapy-induced nausea and vomiting: a prospective randomized controlled study. Future Oncol 2021;17:2041-2056.
Zhou JG, Huang L, Jin SH, et al. Olanzapine combined with 5- hydroxytryptamine type 3 receptor antagonist (5-HT3 RA) plus dexamethasone for prevention and treatment of chemotherapy-induced nausea and vomiting in high and moderate emetogenic chemotherapy: a systematic review and meta-analysis of randomised controlled trials. ESMO Open 2020;5:e000621.
Yanai T, Iwasa S, Hashimoto H, et al. A double-blind randomized phase II dose-finding study of olanzapine 10 mg or 5 mg for the prophylaxis of emesis induced by highly emetogenic cisplatin-based chemotherapy. Int J Clin Oncol 2018;23:382-388.
Chiu L, Chow R, Popovic M, et al. Efficacy of olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis. Support Care Cancer 2016;24:2381-2392.
Hashimoto H, Yanai T, Nagashima K, et al. A double-blind randomized phase II study of 10 versus 5 mg olanzapine for emesis induced by highly emetogenic chemotherapy with cisplatin [abstract]. J Clin Oncol 2016;34:Abstract 10111.
Chow R, Herrstedt J, Aapro M, et al. Olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting: a systematic review, meta-analysis, cumulative meta-analysis and fragility assessment of the literature. Support Care Cancer 2021;29:3439-3459.
Lambiase PD, de Bono JP, Schilling RJ, et al. British Heart Rhythm Society Clinical Practice Guidelines on the Management of Patients Developing QT Prolongation on Antipsychotic Medication. Arrhythm Electrophysiol Rev 2019;8:161-165.
Drugs@FDA: FDA-Approved Drugs. U.S. Food & Drug Administration;
American Society of Clinical O, Kris MG, Hesketh PJ, et al. American society of clinical oncology guideline for antiemetics in oncology: Update 2006. J Clin Oncol 2006;24:2932-2947.
Kris MG, Gralla RJ, Clark RA, et al. Antiemetic control and prevention of side effects of anti-cancer therapy with lorazepam or diphenhydramine when used in combination with metoclopramide plus dexamethasone. A double-blind, randomized trial. Cancer 1987;60:2816- 2822.
James A, Nair MM, Abraham DS, et al. Effect of lorazepam in reducing psychological distress and anticipatory nausea and vomiting in patients undergoing chemotherapy. J Pharmacol Pharmacother 2017;8:112-115.
Pasricha PJ, Pehlivanov N, Sugumar A, Jankovic J. Drug Insight: from disturbed motility to disordered movement--a review of the clinical benefits and medicolegal risks of metoclopramide. Nat Clin Pract Gastroenterol Hepatol 2006;3:138-148.
Kawanishi C, Onishi H, Kato D, et al. Unexpectedly high prevalence of akathisia in cancer patients. Palliat Support Care 2007;5:351-354.
Patanwala AE, Amini R, Hays DP, Rosen P. Antiemetic therapy for nausea and vomiting in the emergency department. J Emerg Med 2010;39:330-336.
van Harten PN, Hoek HW, Kahn RS. Acute dystonia induced by drug treatment. BMJ 1999;319:623-626.
Navari RM, Qin R, Ruddy KJ, et al. Olanzapine for the prevention of chemotherapy-induced nausea and vomiting. N Engl J Med 2016;375:134-142.
Navari RM, Gray SE, Kerr AC. Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial. J Support Oncol 2011;9:188-195.
Gralla R, Lichinitser M, Van Der Vegt S, et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol 2003;14:1570-1577.
Roila F, Warr D, Clark-Snow RA, et al. Delayed emesis: moderately emetogenic chemotherapy. Support Care Cancer 2005;13:104-108.
Kamen C, Tejani MA, Chandwani K, et al. Anticipatory nausea and vomiting due to chemotherapy. Eur J Pharmacol 2014;722:172-179.
Aapro MS, Molassiotis A, Olver I. Anticipatory nausea and vomiting. Support Care Cancer 2005;13:117-121.
Ezzo J, Vickers A, Richardson MA, et al. Acupuncture-point stimulation for chemotherapy-induced nausea and vomiting. J Clin Oncol 2005;23:7188-7198.
Morrow GR, Morrell C. Behavioral treatment for the anticipatory nausea and vomiting induced by cancer chemotherapy. N Engl J Med 1982;307:1476-1480.
Redd WH, Andrykowski MA. Behavioral intervention in cancer treatment: controlling aversion reactions to chemotherapy. J Consult Clin Psychol 1982;50:1018-1029.
